Gainers

• bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million.
• USBC (AMEX:USBC) stock moved upwards by 16.66% to $0.49. The market value of their outstanding shares is at $164.1 million.
• Palatin Techs (NASDAQ:PTN) shares increased by 12.71% to $11.26. The company's market cap stands at $17.7 million.
• Mira Pharmaceuticals (NASDAQ:MIRA) stock rose 12.55% to $0.87. The company's market cap stands at $32.3 million.
• Arcturus Therapeutics (NASDAQ:ARCT) shares moved upwards by 10.8% to $16.36. The company's market cap stands at $419.5 million.
• Minimed Group (NASDAQ:MMED) stock increased by 10.58% to $22.41. The company's market cap stands at $5.7 billion. As per the press release, Q1 earnings came out today.

Losers

• Alumis (NASDAQ:ALMS) stock declined by 57.4% to $9.29 during Tuesday's regular session. The company's market cap stands at $2.8 billion.
• Picard Medical (AMEX:PMI) shares decreased by 44.97% to $4.66. The market value of their outstanding shares is at $17.3 million.
• BioXcel Therapeutics (NASDAQ:BTAI) stock declined by 24.67% to $0.12. The market value of their outstanding shares is at $5.0 million.
• Kala Bio (NASDAQ:KALA) shares declined by 20.62% to $0.53. The market value of their outstanding shares is at $13.0 million.
• Cadrenal Therapeutics (NASDAQ:CVKD) stock declined by 18.29% to $1.43. The market value of their outstanding shares is at $6.2 million.
• Vivos Therapeutics (NASDAQ:VVOS) stock fell 13.37% to $0.17. The company's market cap stands at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.